Skip to Content

Jeffrey E. Gershenwald, MD

Present Title & Affiliation

Primary Appointment

Professor (term-tenured), Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor (term-tenured), Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1990 Cornell University Medical College, New York, NY, MD, M.D. with Honors in Research
1984 Cornell University, Ithaca, NY, BS, B.S. with Honors

Postgraduate Training

1995-1998 Fellow in Surgical Oncology/Junior Faculty Associate, The University of Texas MD Anderson Cancer Center, Houston, TX, Chairman, Dr. Raphael E. Pollock
1994-1995 Administrative Chief Resident (General Surgery), The New York Hospital-Cornell Medical Center, New York, NY, Chairman, Dr. John M. Daly
1991-1994 Resident in General Surgery, The New York Hospital-Cornell Medical Center, New York, NY, Chairman, Dr. Roger Yurt/Dr. John M. Daly
1990-1991 Intern in General Surgery, The New York Hospital-Cornell Medical Center, New York, NY, Chairman, Dr. G. Tom Shires

Board Certifications

1996 American Board of Surgery, Recertification Date: 2004


Academic Appointments

Associate Member, Graduate Faculty, Department of Surgical Oncology, Graduate School of Biomedical Sciences, The University of Texas-Houston, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2001-present

Administrative Appointments/Responsibilities

Medical Director, Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, Balch CM, Ross MI. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16(6):2253-60, 6/1998. PMID: 9626228.
2. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17(3):976-83, 3/1999. PMID: 10071292.
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635-48, 8/2001. PMID: 11504745.
4. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16):3622-34, 8/2001. PMID: 11504744.
5. Gershenwald JE, Fidler IJ. Cancer. Targeting lymphatic metastasis. Science 296(5574):1811-2, 6/2002. PMID: 12052939.
6. Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Kim KB, Papadopoulos NE, Prieto VG, Ross MI. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 20(23):4555-8, 12/2002. PMID: 12454112.
7. Rousseau DL, Jr, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10(5):569-74, 6/2003. PMID: 12794025.
8. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54(3):131-49; quiz 182-4, 5/2004. PMID: 15195788.
9. Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 23(21):4588-90, 7/2005. PMID: 16034040.
10. Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 12(8):587-96, 8/2005. PMID: 16021533.
11. Aloia TA, Gershenwald JE, Andtbacka RH, Johnson MM, Schacherer CW, Ng CS, Cormier JN, Lee JE, Ross MI, Mansfield PF. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 24(18):2858-65, 6/2006. PMID: 16782925.
12. Cormier JN, Xing Y, Ding M, Cantor SB, Salter KJ, Lee JE, Mansfield PF, Gershenwald JE, Ross MI. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol 25(17):2442-8, 6/2007. PMID: 17557957.
13. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99(8):1265-8, 10/21/2008. e-Pub 9/23/2008. PMID: 18813315.
14. Staquicini FI, Tandle A, Libutti SK, Sun J, Zigler M, Bar-Eli M, Aliperti F, Pérez EC, Gershenwald JE, Mariano M, Pasqualini R, Arap W, Lopes JD. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res 68(20):8419-28, 10/2008. PMID: 18922915.
15. Rebhun RB, Lazar AJ, Fidler IJ, Gershenwald JE. Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Met 25(3):191-9, 2008.
16. Gershenwald JE, Andtbacka RHI, Prieto VG, Johnson MM, Diwan AH, Lee JE, Mansfield PF, Cormier JN, Schacherer CW, Ross MI. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 26(26):4296-4303, 2008. e-Pub 7/2008. PMID: 18606982.
17. Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, Kim K, Webster K, Cella D, Palmer JL. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer 112(10):2249-57, 2008.
18. Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 115(11):2505-13, 3/2009. PMID: 19309746.
19. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw 7(3):308-17, 3/2009. PMID: 19401063.
20. Tellez CS, Shen L, Estécio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Res 19(3):146-55, 6/2009. PMID: 19441164.
21. Petersson F, Diwan AH, Ivan D, Gershenwald JE, Johnson MM, Harrell R, Prieto VG. Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. J Cutan Pathol 36(11):1157-63, 11/2009. e-Pub 2/5/2009. PMID: 19222695.
22. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK. Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 27(36):6199-206, 12/2009. PMCID: PMC2793035.
23. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15(24). e-Pub 12/2009. PMCID: PMC2805170.
24. Scoggins CR, Martin RC, Ross MI, Edwards MJ, Reintgen DS, Urist MM, Gershenwald JE, Sussman JJ, Dirk Noyes R, Goydos JS, Beitsch PD, Ariyan S, Stromberg AJ, Hagendoorn LJ, McMasters KM. Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma Patients. Ann Surg Oncol 17(3):709-17, 2009. PMID: 19967459.
25. Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, Powell B, Ross MI, Sondak VK, Thompson JF. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 60(5):872-5, 2009. PMID: 19389531.
26. Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 116(9):2234-41, 5/1/2010. PMCID: PMC2860044.
27. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28(14):2452-9, 5/10/2010. e-Pub 4/5/2010. PMID: 20368546.
28. Bowles TL, Xing Y, Hu CY, Mungovan KS, Askew RL, Chang GJ, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN. Conditional Survival Estimates Improve Over 5 Years for Melanoma Survivors with Node-Positive Disease. Ann Surg Oncol 17(8):2015-23, 8/2010. e-Pub 4/6/2010. PMID: 20369298.
29. Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P, AJCC Melanoma Task Force. Predicting survival outcome of localized melanoma: An electronic prediction tool based on the AJCC melanoma database. Ann Surg Oncol 17(8):2006-14, 8/2010. e-Pub 4/2010. PMID: 20379784.
30. Chang SB, Askew RL, Xing Y, Weaver S, Gershenwald JE, Lee JE, Royal R, Lucci A, Ross MI, Cormier JN. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol 17(10):2764-72, 10/2010. e-Pub 3/25/2010. PMCID: PMC2943041.
31. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem P. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 63(5):751-61, 11/2010. PMCID: PMC2956767.
32. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17(2):229-35, 2010. PMID: 20975100.
33. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103(2):129-42, 2010. PMID: 21081714.
34. Wei X, Prickett TD, Viloria CG, Molinolo A, Lin JC, Cardenas-Navia I, Cruz P, NISC Comparative Sequencing Program, Rosenberg SA, Davies MA, Gershenwald JE, López-Otín C, Samuels Y. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol Cancer Res 8(11):1513-25, 2010. PMID: 21047771.
35. Wang LE, Huang YJ, Yin M, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer 47(1):107-15, 1/2011. e-Pub 7/23/2010. PMCID: PMC2987546.
36. Patnana M, Bronstein Y, Szklaruk J, Bedi DG, Hwu WJ, Gershenwald JE, Prieto VG, Ng CS. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol 66(3):224-36, 3/2011. e-Pub 1/9/2011. PMID: 21295201.
37. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, NISC Comparative Sequencing Program, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43(5):442-6, 5/2011. e-Pub 4/15/2011. PMID: 21499247.
38. Moore-Olufemi S, Herzog C, Warneke C, Gershenwald JE, Mansfield P, Ross M, Prieto V, Lally KP, Hayes-Jordan A. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg 253(6):1211-5, 6/2011. PMID: 21451389.
39. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC, Morton DL, Sondak VK. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 29(16):2199-205, 6/1/2011. e-Pub 4/25/2011. PMCID: PMC3107741.
40. Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 17(14):4882-91, 7/15/2011. e-Pub 6/1/2011. PMCID: PMC3139726.
41. Askew RL, Swartz RJ, Xing Y, Cantor SB, Ross MI, Gershenwald JE, Palmer JL, Lee JE, Cormier JN. Mapping FACT-Melanoma Quality-of-Life Scores to EQ-5D Health Utility Weights. Value Health 14(6):900-6, Sep-Oct, 9/2011. e-Pub 6/24/2011. PMID: 21914512.
42. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-42, 11/15/2011. e-Pub 11/2/2011. PMCID: PMC3219136.
43. White RL, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, Pockaj BA, Essner R, Faries M, Charney KJ, Avisar E, Hauschild A, Egberts F, Averbook BJ, Garberoglio CA, Vetto JT, Ross MI, Chu D, Trisal V, Hoekstra H, Whitman E, Wanebo HJ, Debonis D, Vezeridis M, Chevinsky A, Kashani-Sabet M, Shyr Y, Berry L, Zhao Z, Soong SJ, Leong SP, Sentinel Lymph Node Working Group. Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database. Ann Surg Oncol 18(13):3593-600, 12/2011. e-Pub 6/7/2011. PMID: 21647761.
44. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S, Schacherer CW, Gardner JM, Wang Y, Bishop DT, Barrett JH, GenoMEL Investigators, MacGregor S, Hayward NK, Martin NG, Duffy DL, Q-Mega Investigators, Mann GJ, Cust A, Hopper J, AMFS Investigators, Brown KM, Grimm EA, Xu Y, Han Y, Jing K, McHugh C, Laurie CC, Doheny KF, Pugh EW, Seldin MF, Han J, Wei Q. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 20(24):5012-23, 12/15/2011. e-Pub 9/17/2011. PMID: 21926416.
45. Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH, Samuels Y. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43(11):1119-26, 2011. e-Pub 9/25/2011. PMID: 21946352.
46. Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014-23, 8/2012. e-Pub 12/2011. PMCID: PMC3310961.
47. Boland GM, Gershenwald JE. Sentinel lymph node biopsy in melanoma. Cancer J 18(2):185-91, 3/2012. PMID: 22453020.
48. Mu H, Calderone TL, Davies MA, Prieto VG, Wang H, Mills GB, Bar-Eli M, Gershenwald JE. Lysophosphatidic Acid Induces Lymphangiogenesis and Interleukin-8 Production in Vitro in Human Lymphatic Endothelial Cells. Am J Pathol 180(5):2170-81, 5/2012. e-Pub 3/30/2012. PMID: 22465753.
49. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. A landscape of driver mutations in melanoma. Cell 150(2):251-63, 7/20/2012. PMID: 22817889.

Invited Articles

1. Pawlik TM, Ross MI, Gershenwald JE. Lymphatic mapping in the molecular era. Ann Surg Oncol 11(4):362-74, 4/2004. PMID: 15070595.
2. Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma. Curr Probl Surg 42(7):455-534, 2005.
3. Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Onc Clin N Am 16(2):430-30, 2007.
4. Gershenwald JE, Ross MI. Practice point: Is sentinel-node biopsy superior to nodal observation in melanoma? Nat Clin Pract Oncol 4(5):278-9, 2007.
5. Gershenwald JE, Petrelli N. Fellowship training in surgical oncology - an international affair. Surg Oncol 17(4):277-9, 12/2008. e-Pub 7/2008. PMID: 18672361.
6. Berman R, Kurtzman S, Posner M, Gershenwald. Society of Surgical Oncology fellowship training - Where we have been, where we are now, and where we are going. J Surg Oncol 100(3):179-81, 9/1/2009. e-Pub 5/2009. PMID: 19444817.
7. Ross MI, Thompson JF, Gershenwald JE. Sentinel lymph node biopsy for melanoma: Critical assessment at its twentieth anniversary. Surg Oncol Clin N Am 20(1):57-78, 1/2011. PMID: 21111959.
8. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am 20(1):1-17, 1/2011. PMID: 21111956.
9. Davies MA, Gershenwald JE. Targeted therapy for melanoma: A primer. Surg Oncol Clin N Am 20(1):165-80, 1/2011. PMCID: PMC3031081.
10. Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A, Kashani-Sabet M. Cutaneous melanoma: A model to study cancer metastasis. J Surg Oncol 103(6):538-49, 5/2011. PMID: 21480247.
11. Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC, Sleeman JP, Gershenwald JE. Lymphangiogenesis and hemangiogenesis: Potential targets for therapy. J Surg Oncol 103(6):489-500, 5/2011. PMID: 21480241.
12. Gershenwald JE, Ross MI. Sentinel lymph node biopsy for cutaneous melanoma. N Eng J Med 364(18):1738-45, 2011. e-Pub 5/2011.
13. Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol 104(4):341-53, 9/2011. PMID: 21858828.


1. Gershenwald JE, Coit DG, Sondak VK, Thompson JF. The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. Ann Surg Oncol 19(11):3301-3, 10/2012. e-Pub 8/2012. PMID: 22868918.
2. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM Staging System for Cutaneous Melanoma and Beyond. Ann Surg Oncol 17(6):1475-77, 2010. PMID: 20300965.
3. Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1). Ann Surg Oncol 15(3):670-3, 2008.

Book Chapters

1. Patnana M, Gershenwald JE, Hwu WJ, Ng CS. Diagnostic imagings for the radiologists, medical oncologists and surgical oncologists. In: Oncologic Imaging for the Practicing Radiologist, Medical Oncologist and Surgeon. Ed(s) Silverman PM. Bermedica Production, Ltd. Columbia, 1-19, 2011.
2. Andtbacka RI, Gershenwald JE. Lymphatic mapping and sentinel lymph node biopsy. In: Cancer Metastasis: Biologic Basis and Therapeutics. Ed(s) Lyden D, Welch DR, Psaila B. Cambridge: New York, 501-15, 2011.
3. Gershenwald JE. Prognostic factors and staging in melanoma. In: Cancer of the Skin, 2nd. Ed(s) Rigel DS, Robinson JK, Ross M, Friedman RJ, Cockerell CJ, Lim HW, Stockfleth E, Kirkwood JM. Elsevier Inc. United Kingdom, 282-94, 2011.
4. Gershenwald JE, Ballo MT, Myers JN. Regional management of melanoma in the clinically node-negative neck. In: Cutaneous Malignancy of the Head and Neck. Ed(s) Weber RS, Moore BA. Plural Publishing, Inc. San Diego, CA, 343-71, 2011.
5. Gershenwald JE, Hwu Patrick. Melanoma. In: Cancer Medicine, 8th. Ed(s) WK Hong, RC Bast, WN Hait, DW Kufe, R Pollock, RR Weichselbaum, JF Holland, E Frei, III. People's Medical Publishing House - USA: Shelton, 1459-86, 2010.
6. Gershenwald JE, Balch CM, Thompson JF. Intraoperative mapping and sentinel node technology. In: Cutaneous Melanoma, 5th. Ed(s) Balch CM, Houghton AN, Sober AJ, Soong S, Atkins MB, Thompson JF. Quality Medical Publishing: St. Louis, 2009.
7. Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd D, Buzaid AC, Cochran A, Coit DG, Ding S, Eggermont AMM, Flaherty KT, Gimotty P, Kirkwood J, McMasters K, Mihm M, Morton D, Ross MI, Sober A, Sondak VK. Melanoma of the skin. In: AJCC Cancer Staging Manual, 7th. Ed(s) Edge SE, Byrd DR, Carducci MA, Compton CA. Springer: New York, 2009.
8. Balch CM, Gershenwald JE, Soong S, Sober A, Kirkwood J. Melanoma staging and classification. In: Cutaneous Melanoma, 5th. Ed(s) Balch CM, Houghton AN, Sober AJ, Soong S, Atkins MB, Thompson JF. Quality Medical Publishing: St. Louis, 65-85, 2009.
9. Gershenwald JE, Balch CM, Soong S, Thompson JF. Prognostic factors and natural history of melanoma. In: Cutaneous Melanoma, 5th. Ed(s) Balch CM, Houghton AN, Sober AJ, Soong S, Atkins MB, Thompson JF. Quality Medical Publishing: St. Louis, 35-64, 2009.
10. Pytowski B, Gershenwald JE. Therapeutic targeting of the lymphovascular system in cancer: The promise and challenges. In: From Local Invasion to Metastatic Cancer: Involvement of Distant Sites through the Lymphovascular System. Ed(s) Leong SP. Humana Press: New York, 191-200, 2009.

Books (edited and written)

1. Gershenwald, JE, Guest Editor. Ed(s) N Petrelli. Surgical Oncology Clinics of North America. In: Melanoma. 20, 1. Elsevier, Health Sciences: Philadelphia, PA, 2011.
2. Gershenwald JE, Guest Editor. Lymphadenectomy for Malignant Disease. Operative Techniques in General Surgery: New York, 2006.

Grant & Contract Support

Title: Clinicopathologic and Molecular Staging & Prognosis in Early-Stage Melanoma
Funding Source: Melanoma Research Alliance, Team Science Award
Role: Principal Investigator
Duration: 8/1/2011 - 7/31/2014
Title: UT MD Anderson Cancer Center SPORE in Melanoma (Core B)
Funding Source: NIH/NCI
Role: Co-Director
Principal Investigator: Grimm, E
Duration: 6/1/2010 - 5/31/2015
Title: UT MD Anderson Cancer Center SPORE in Melanoma (Core A)
Funding Source: NIH/NCI
Role: Co-Director
Principal Investigator: Grimm, E
Duration: 6/1/2010 - 5/31/2015

Last updated: 8/17/2015